Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160262 · ClinicalTrials.gov registry record · Phase 3
Open-label Safety Study in Adults With ADHD
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 724
- Enrollment target
NCT02160262 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 724 participants.
The verdict
NCT02160262, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 724 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
- DRUG Dasotraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02160262
The ClinicalTrials.gov registry entry for NCT02160262 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 724 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dasotraline is the first listed.
NCT02160262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02160262 about?
NCT02160262 is a clinical study titled "Open-label Safety Study in Adults With ADHD". To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
What is the current status of trial NCT02160262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 724 participants. The study started on 2014-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02160262?
The interventions under investigation include: Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02160262?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.